To compare the effects of enriched ethyl-eicosapentaenoic acid (E-EPA) omega-3 fatty acid supplementation with those of placebo on hot flashes (HFs) and quality of life among middle-aged women.
Women were considered for participation if they were between 40 and 55 years of age and had moderate to severe psychological distress. A total of 120 women were randomly assigned to E-EPA or placebo for 8 weeks. Only women with HFs were included in this analysis (E-EPA, n = 45; placebo, n = 46). Outcomes were changes from baseline to week 8 postintervention regarding hot flash (HF) frequency (number of HFs per day), intensity and score (frequency × intensity), and Menopause-specific Quality of Life questionnaire scores.
At baseline, the average number of HFs was 2.8 per day. After 8 weeks, HF frequency and score decreased significantly in the E-EPA group compared with the placebo group. There was no difference in the change in HF intensity between groups. Frequency of HFs declined by a mean of 1.58 per day (95% CI, −2.18 to −0.98) in the E-EPA group and by 0.50 per day (95% CI, −1.20 to 0.20) in the placebo group. The odds of being a responder among those taking E-EPA were about three times greater than among those taking placebo (odds ratio, 2.70; 95% CI, 1.03-7.03; P = 0.04). Menopause-Specific Quality of Life scores improved significantly over time in both groups but no significant differences were noted between them.
Supplementation with E-EPA omega-3 fatty acid reduced HF frequency and improved the HF score relative to placebo. These results need to be confirmed by a clinical trial specifically designed to evaluate HFs in more symptomatic women.
E-EPA omega-3 supplementation reduced hot flash(HF) frequency and improved the HF score relative to placebo. These results need to be confirmed by a clinical trial specifically designed to evaluate HF in more symptomatic women.
From the 1Saint-François d'Assise Hospital (Centre Hospitalier Universitaire de Québec); 2Department of Psychiatry, Robert Giffard Research Centre; and 3Department of Obstetrics and Gynecology, Laval University, Québec, Canada.
Received May 8, 2008; revised and accepted July 10, 2008.
Funding/support: This work was supported by the Lucie and André Chagnon Chair for the Teaching of an Integrated Approach in Prevention, Laval University.
Financial disclosure: Dr Lucas has received speaking honoraria and travel expenses from Isodis Natura. No other authors have reported financial disclosures related to the present manuscript.
Trial Registration: International Standard Randomized Controlled Trial Number ISRCTN69617477 (http://www.controlled-trials.com).
Address correspondence to: Michel Lucas, PhD, RD, Saint-François d'Assise Hospital (CHUQ), Laval University, Room D6-701, 45 Leclerc St, Quebec, Canada G1L 2G1. E-mail: email@example.com